Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Lesniak, Maciej S  [Clear All Filters]
2023
Zannikou M, Duffy JT, Levine RN, Seblani M, Liu Q, Presser A, Arrieta VA, Chen CJ, Sonabend AM, Horbinski CM, et al. IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM. J Immunother Cancer. 2023;11(2).
2022
Xuan W, Hsu W-H, Khan F, Dunterman M, Pang L, Wainwright DA, Ahmed AU, Heimberger AB, Lesniak MS, Chen P. Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma. Cancer Immunol Res. 2022.
2021
Fares J, Ahmed AU, Ulasov IV, Sonabend AM, Miska J, Lee-Chang C, Balyasnikova IV, Chandler JP, Portnow J, Tate MC, et al. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. Lancet Oncol. 2021.
2016
Roth S, Dreixler JC, Mathew B, Balyasnikova I, Mann JR, Boddapoti V, Xue L, Lesniak MS. Hypoxic-Preconditioned Bone Marrow Stem Cell Medium Significantly Improves Outcome After Retinal Ischemia in Rats. Invest Ophthalmol Vis Sci. 2016;57(7):3522-3532.
2015
Alexiades NG, Auffinger B, Kim CKwon, Hasan T, Lee G, Deheeger M, Tobias AL, Kim J, Balyasnikova I, Lesniak MS, et al. MMP14 as a novel downstream target of VEGFR2 in migratory glioma-tropic neural stem cells. Stem Cell Res. 2015;15(3):598-607.
2013
Balyasnikova IV, Prasol MS, Ferguson SD, Han Y, Ahmed AU, Gutova M, Tobias AL, Mustafi D, Rincón E, Zhang L, et al. Intranasal Delivery of Mesenchymal Stem Cells Significantly Extends Survival of Irradiated Mice with Experimental Brain Tumors. Mol Ther. 2013.
Gutova M, Frank JA, D'Apuzzo M, Khankaldyyan V, Gilchrist MM, Annala AJ, Metz MZ, Abramyants Y, Herrmann KA, Ghoda LY, et al. Magnetic Resonance Imaging Tracking of Ferumoxytol-Labeled Human Neural Stem Cells: Studies Leading to Clinical Use. Stem Cells Transl Med. 2013.
Ahmed AU, Thaci B, Tobias AL, Auffinger B, Zhang L, Cheng Y, Kim CKwon, Yunis C, Han Y, Alexiades NG, et al. A Preclinical Evaluation of Neural Stem Cell-Based Cell Carrier for Targeted Antiglioma Oncolytic Virotherapy. J Natl Cancer Inst. 2013;105(13):968-977.
Tobias AL, Thaci B, Auffinger B, Rincón E, Balyasnikova IV, Kim CKwon, Han Y, Zhang L, Aboody KS, Ahmed AU, et al. The Timing of Neural Stem Cell-Based Virotherapy Is Critical for Optimal Therapeutic Efficacy When Applied With Radiation and Chemotherapy for the Treatment of Glioblastoma. Stem Cells Transl Med. 2013.